Wenzhen Ge

Wenzhen Ge

Auto-generated profile, based on publicly available information

Wenzhen Ge

Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2021 in Leukemia & Lymphoma
Verified
Journal Article
Open access
GKGena Kanas
Gena Kanas
WGWenzhen Ge
Wenzhen Ge
RQRuben G. W. Quek
Ruben G. W. Quek
KKKatie Keeven
Katie Keeven
KNKnar Nersesyan
Knar Nersesyan
JAJon E. Arnason
Jon E. Arnason
Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) treatments have been rapidly evolving for patients treated in later lines of therapy (LoT). Country-specific cancer registry data for the US and Western Europe (WE) were combined with physician survey results to project the incidence, prevalence, and number of DLBCL and FL patients eligible for and treated by LoT between 2020 and 2025. The total number of incidents and prevalent cases of DLBCL and FL is expected to increase between 2020 and 2025 in the US and WE. 56% and 53% of the third line plus (3L+) eligible DLBCL patients and 60% and 55% of eligible FL patients initiated treatment in the US and WE, respectively. Further research is warranted to understand the reasons behind the high proportion of treatment eligible patients who do not initiate treatment, and potential differences between countries, especially in the 3L + settings.

1 July 2024 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
WGWenzhen Ge
Wenzhen Ge
NWNing Wu
Ning Wu
CCChieh-I Chen
Chieh-I Chen
TITimothy J Inocencio
Timothy J Inocencio
PLPatrick R LaFontaine
Patrick R LaFontaine
EREmily S Ruiz
Emily S Ruiz
Background: Prior to the Food and Drug Administration approval of cemiplimab in 2018, the median overall survival (OS) for adult patients with advanced CSCC receiving systemic therapy was approximately 8 to 15 months. Limited real-world data are available on cemiplimab for this indication in the US. Patients and Methods: This retrospective cohort study included US patients with advanced CSCC initiating cemiplimab monotherapy in a real-world database (2018– 2021). A clinical trial–like sub-cohort was identified using select criteria. Time to treatment discontinuation (TTD), time to next treatment (TTNT), and OS were estimated using Kaplan–Meier methods. Cox proportional hazard models were used to examine prognostic factors associated with OS in the main cohort. Results: The main cohort included 622 patients (n = 240 in the trial-like cohort). In the main cohort, the median age was 78 years, 77.8% were male, 21.4% were immunocompromised/immunosuppressed, and 63.8% had metastatic CSCC. Median (95% CI) TTD and TTNT were 8.0 (6.6– 9.0) months and 16.4 (13.3– 21.0) months, respectively, in the main cohort. Median (95% CI) OS was 24.8 (21.8– 29.1) months in the main cohort (not reached in the trial-like cohort). In multivariable analyses, age < 60 years (hazard ratio [HR], 0.37), Eastern Cooperative Oncology Group performance status < 3– 4 (HR range, 0.13– 0.57), and primary CSCC location in the head and neck only versus extremities only (HR, 0.59) were associated with better OS. Similar OS was observed between patients who had immunosuppressing/immunocompromising conditions and those without. Conclusion: These findings confirm the effectiveness of cemiplimab among a heterogenous, real-world advanced CSCC patient population and substantiate the efficacy of cemiplimab observed in clinical trials.

10 August 2022 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
WGWenzhen Ge
Wenzhen Ge
NWNing Wu
Ning Wu
RQRuben G. W. Quek
Ruben G. W. Quek
JLJinjie Liu
Jinjie Liu
JPJean-Francois Pouliot
Jean-Francois Pouliot
SAScott J. Antonia
Scott J. Antonia
Introduction Contemporary real-world data on advanced non-small cell lung cancer (aNSCLC) treatment patterns across programmed cell death-ligand 1 (PD-L1) expression levels and testing status are limited. Methods A retrospective cohort was selected of adults newly diagnosed with aNSCLC between January 1, 2018, and July 31, 2021, who initiated first-line treatments, which were described by PD-L1 status and expression levels (≥ 50%, 1–49%, < 1%). Treatment received before and after PD-L1 test results were described for patients initiating first-line treatment before PD-L1 results. For patients who initiated chemotherapy alone before PD-L1 results, the probability of receiving immune checkpoint inhibitors (ICIs) after PD-L1 results was estimated by PD-L1 level and associated factors were explored. Results Among 12,202 patients with aNSCLC initiating first-line treatment [54.7% male, mean (standard deviation) age 69.2 (9.4) years], the most common therapies were ICI-based regimens across PD-L1 levels, and chemotherapy alone among PD-L1-untested patients. Use of chemotherapy alone decreased between 2018 and 2019 and stabilized thereafter, accounting for 21–29% of first-line treatments across PD-L1 levels and 48% of untested patients in 2021. Of 1468 patients initiating first-line treatment before PD-L1 results, treatments remained unchanged in most patients after PD-L1 results. Among patients initiating chemotherapy alone before PD-L1 results, the probability of receiving ICIs within 45 days after test results was 40.5% [95% confidence interval (CI) 31.6–48.3%], 28.6% (95% CI 20.3–36.0%), and 22.9% (95% CI 16.9–28.4%) at PD-L1 ≥ 50%, 1–49%, and < 1%, respectively. Conclusion While ICI-based regimens accounted for most first-line treatments across PD-L1 levels, chemotherapy alone was initiated in > 20% of patients tested for PD-L1 and 48% of untested patients in 2021. Patients who initiated chemotherapy alone had a low probability of receiving ICIs after PD-L1 test results. These results highlight the need for understanding the role and timing of PD-L1 test results for informing treatment decisions for patients with aNSCLC.

23 June 2022 in Future Oncology
Verified
Journal Article
Open access
WGWenzhen Ge
Wenzhen Ge
CCChieh-I Chen
Chieh-I Chen
NWNing Wu
Ning Wu
MFMatthew G Fury
Matthew G Fury
EREmily Ruiz
Emily Ruiz
JJJessica J Jalbert
Jessica J Jalbert
Aims: To examine real-world treatment patterns for Hedgehog pathway inhibitors (HHIs) for the treatment of advanced basal cell carcinoma. Patients & methods: HHI initiators between January 2013 and... Plain language summary This study examined patterns of discontinuation and reinitiation of Hedgehog pathway inhibitors (HHIs) such as vismodegib or sonidegib for patients with basal cell carcinoma,...

14 November 2023 in Future Oncology
Verified
Journal Article
Closed access
WGWenzhen Ge
Wenzhen Ge
CCChieh-I Chen
Chieh-I Chen
NWNing Wu
Ning Wu
MFMatthew G Fury
Matthew G Fury
EREmily Ruiz
Emily Ruiz
JJJessica J Jalbert
Jessica J Jalbert

13 October 2026 in Hepatology
Verified
Journal Article
Open access
PNPriyanka Nakka
Priyanka Nakka
BHBrian D. Hobbs
Brian D. Hobbs
CSCarlo Sidore
Carlo Sidore
WPWilliam H. Palmer
William H. Palmer
DMDana Murdock
Dana Murdock
MFManuel A.R. Ferreira
Manuel A.R. Ferreira
Background and Aims: Distinct autoimmune diseases can share symptoms and autoantibodies, but the molecular pathways underlying this shared etiology remain poorly understood. We assessed genetic support for IL12 signaling across 27 diseases. Approach and Results: We identified a rare variant upstream of IL12A with large risk-increasing effects on autoimmune hepatitis [AIH; per-allele odds ratio (OR)=2.98, p =3×10 −9 ], primary biliary cholangitis (PBC; OR=2.80, p =2×10 −8 ), systemic sclerosis (SSc; OR=2.64, p =2×10 −11 ), Sjogren's disease (SjD; OR=1.94, p =10 −11 ), systemic lupus erythematosus (SLE; OR=1.83, p =5×10 −10 ) and multiple sclerosis (OR=1.79, p =10 −11 ). Lifetime risk for developing at least one of these conditions increased 6-fold in homozygote carriers (OR=5.73, p =0.003). We then evaluated genetic support for all 4 IL12 signaling genes and found that: (i) a non-coding variant downstream of IL12A (linked to lower gene expression) protected against 5 of the 6 diseases; (ii) an intronic variant in IL12RB2 (linked to higher gene expression) increased risk of all 6 diseases; and (iii) heterozygote carriers of rare predicted loss-of-function or missense variants in IL12RB2 had 18% lower odds of SLE (OR=0.82, p =2×10 −5 ). IL23 signaling, which shares ligand and receptor subunits with IL12, was not associated with these conditions. In epidemiologic analyses of co-prevalence, 5 of the 6 diseases strongly co-occurred with each other: AIH, PBC, SSc, SjD and SLE. Conclusions: AIH, PBC, SSc, SjD and SLE represent a distinct subset of autoimmune diseases that share genetic associations with the IL12 pathway, as well as profound co-prevalence, suggesting they may have a shared etiology and may respond to the same targeted therapeutic intervention(s).